Major depression during dexfenfluramine treatment
Toornvliet, A.C.; Pijl, H.; Meinders, A.E.
International Journal of Obesity and Related Metabolic Disorders Journal of the International Association for the Study of Obesity 18(9): 650
1994
ISSN/ISBN: 0307-0565 PMID: 7812421 Document Number: 428836
Document emailed within 1 workday
Related Documents
Maes, M.; Mihaylova, I.; Kubera, M.; Leunis, J.-C. 2008: An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS Neuro Endocrinology Letters 29(3): 313-319Enzi, G. 1997: A multicenter open study of dexfenfluramine in Italy. the efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. the DIMOS Group Terapevticheskii Arkhiv 69(5): 71-75
2011: Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice Prescrire International 20(116): 128-133
Epperson, C.N. 1999: Postpartum major depression: detection and treatment American Family Physician 59(8): 2247-2254; 2259-2260
Torta, R.; Ala, G.; Borio, R.; Cicolin, A.; Costamagna, S.; Fiori, L.; Ravizza, L. 1993: Rubidium chloride in the treatment of major depression Minerva Psichiatrica 34(2): 101-110
Bhatia, S.C.; Bhatia, S.K. 1997: Major depression: selecting safe and effective treatment American Family Physician 55(5): 1683-1698
Karasu, T.B. 1994: The role of individual psychotherapy in the treatment of major depression Comprehensive Therapy 20(2): 101-105
Marangell, L.B. 2001: Switching antidepressants for treatment-resistant major depression Journal of Clinical Psychiatry 62(Suppl): 12-17
Datka, W.; Siwek, M.; Dudek, D.; Maczka, G.; Zieba, A. 2007: Working memory disturbances in patients with major depression after ECT treatment Psychiatria Polska 41(3): 339-349
McGrath, P.J.; Stewart, J.W.; Petkova, E.; Quitkin, F.M.; Amsterdam, J.D.; Fawcett, J.; Reimherr, F.W.; Rosenbaum, J.F.; Beasley, C.M. 2000: Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression Journal of Clinical Psychiatry 61(7): 518-524
Vella, G.; Loriedo, C.; Raccah, R.; Baldassarre, P.; Paolillo, A. 1998: Successful paroxetine treatment of major depression in an adult form of metachromatic leukodystrophy with cognitive disturbances Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 43(7): 748-749
Olivera, A.A.; Fero, D.; Evans, M. 1988: Major depression, anxiety, and substance abuse in a multiple sclerosis patient: diagnosis, treatment, and outcome Journal of Clinical Psychiatry 49(2): 78
Goodnick, P.J.; Fieve, R.R.; Peselow, E.D.; Barouche, F.; Schlegel, A. 1987: Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGi change Psychopharmacology Bulletin 23(1): 162-163
Feighner, J.; Targum, S.D.; Bennett, M.E.; Roberts, D.L.; Kensler, T.T.; D'Amico, M.F.; Hardy, S.A. 1998: A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression Journal of Clinical Psychiatry 59(5): 246-253
Frank, E.; Grochocinski, V.J.; Spanier, C.A.; Buysse, D.J.; Cherry, C.R.; Houck, P.R.; Stapf, D.M.; Kupfer, D.J. 2000: Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression Journal of Clinical Psychiatry 61(1): 51-57
Spalletta, G.; Caltagirone, C. 2003: Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms Functional Neurology 18(4): 227-232
Beasley, C.M.; Nilsson, M.E.; Koke, S.C.; Gonzales, J.S. 2000: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose Journal of Clinical Psychiatry 61(10): 722-728
Maes, M.; Mihaylova, I.; Leunis, J.-C. 2007: Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression Neuro Endocrinology Letters 28(6): 861-867
Gervasoni, N.; Bertschy, G. 2008: The major depression with psychotic symptoms Revue Medicale Suisse 4(171): 1984-1987
Weissman, M.M. 1981: Women: the major victims of depression Medical Times 109(1): 24s-36s